|
Accueil > Actualité
Novavax : manages to reduce losses in 2024
(CercleFinance.com) - Novavax announces that sales reached $682 million in 2024, down 30% on the previous year, while operating expenses also fell sharply, from $1,550 million to $931 million.
The laboratory managed to significantly reduce its losses: after a loss of $545 million last year, Novavax recorded a more limited loss of $187 million in 2024. As a result, diluted EPS came out at -$1.23 vs. -$5.41 in 2023. "In 2024, we unveiled our new growth strategy, shifting our focus from commercializing our COVID-19 vaccine to leveraging our leading technology platform," said John C. Jacobs, President and CEO of Novavax. Looking ahead to 2025 and beyond, we believe we are well positioned to create significant value for all stakeholders', he added. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
11/04/2025 17:33
VallourecBoston Partners Global Investors franchit les 5% 11/04/2025 16:58 Société Généraleen vert, un broker relève sa cible 11/04/2025 16:41 Orangetitre en hausse, un broker relève sa cible 11/04/2025 15:59 KKRacquiert 5% de Enilive, portant sa participation à 30% 11/04/2025 15:52 Havasbien orienté après son point trimestriel 11/04/2025 15:32 EniKKR augmente sa participation à 30% dans Enilive Tous les articles sociétés |
